David's Milkberry (Chiococca alba): A Comprehensive Reference
Identity: Botanical and Chemical Classification
Accepted Scientific Name and Taxonomy
Chiococca alba is a species of flowering plant in the coffee family (Rubiaceae), native to Florida and the extreme southern tip of Texas in the United States, Bermuda, Mexico, Central America, the Caribbean, the Galápagos, and tropical South America. Common names include David's milkberry, West Indian milkberry, cahinca, and West Indian snowberry.
The genus name Chiococca is derived from the Greek words chion (snow) and kokkos (berry), referring to the plant's distinctive white, snow-like fruits. The specific epithet alba is Latin for "white," alluding to the color of the drupes.
Nomenclatural History
Chiococca alba was originally described by Carl Linnaeus as Lonicera alba in his seminal work Species Plantarum in 1753, based on specimens from Jamaica. In 1893, Albert Spear Hitchcock transferred the species to the genus Chiococca in a report from the Missouri Botanical Garden, establishing its current binomial nomenclature.
A form from Bermuda was described as a distinct species, Chiococca bermudiana, by Stewardson Brown in 1909, but has since been widely regarded as a synonym of C. alba.
Additional published synonyms accepted by the Global Biodiversity Information Facility (GBIF) include Chiococca anguifuga Mart., Chiococca brachiata Ruiz & Pav., and Chiococca racemosa L., among many infraspecific variants.
Regional and Folk Names
The plant is known locally in Brazil by several names including cipó-cruzeiro, cainca, cainana, caninana, cipó-cruz, purga-preta, raiz-preta, raiz-fedorenta, and dambre.
Botanical Description and Habit
West Indian milkberry is an evergreen woody vine or scrambling shrub that often grows on other vegetation and may reach a height of 6 m (20 ft).
The opposite, simple leaves are 5–11 cm (2.0–4.3 in) long and may be elliptic to ovate or broadly lanceolate in shape. Yellow, bell-shaped flowers up to 1 cm (0.39 in) in length appear throughout the year on racemes or panicles of six to eight. The fruit is a white drupe 4–7 mm (0.16–0.28 in) in diameter that generally contains two dark brown seeds.
The plant thrives in wet tropical climates and can be found in a variety of habitats, including forests and coastal areas.
Common Preparations and Supplement Forms
Indigenous communities and traditional healers have valued Chiococca alba for its medicinal properties; the roots, in particular, have been used to brew teas and decoctions.
The roots of this plant find various applications in herbal medicine, including as laxatives, emetic diuretics, and antidiarrheals. For these uses, the plant has been sold commercially in Europe and the United States. The roots are used in various pharmaceutical preparations.
The plant is encountered in contemporary commerce in the form of dried root powders, aqueous decoctions, ethanolic extracts, and as an ingredient in multi-herb liquid formulations. Methanolic and ethanolic root extracts have been the most frequently studied forms in the scientific literature.
Traditional and Historical Use
Brazilian and South American Folk Medicine
In Brazilian traditional medicine, C. alba is used to treat a wide variety of ailments.
Its roots are used as a diuretic, an anti-viral, an anti-inflammatory, and as a treatment for rheumatism, hysteria, and snakebites. Although the use of the leaves is less frequent, leaves have been used to treat asthma, headaches, and diarrhea.
The roots of Chiococca alba have been employed to treat rheumatic disorders and for other therapeutic purposes in Brazil and elsewhere.
Yucatec Maya and Central American Use
Traditional healers of the Yucatec Maya in southern Belize, Central America, have used the infusion of C. alba roots to treat fever, colds, muscle pains, rheumatism, asthma, and inflammations and as antimicrobial and insecticidal/repellent agents.
The plant was used for medicinal purposes by the Yucatec Maya traditional healers of Southern Belize, in Central America, to treat fever, cold, and muscle pains.
Caribbean and Lucayan Archipelago Use
Chiococca alba occurs on all island groupings in the Lucayan Archipelago as well as the southern United States, the Caribbean region, and Central and South America. It is used in the Lucayan Archipelago for general strengthening teas, and to treat bed wetting and tuberculosis.
The plant has a long history of use in traditional medicine across the Caribbean and Central America, where roots and leaves were brewed into tonics.
European Pharmacopoeial Recognition
C. alba is also used as an antiviral, antiedema, and snakebite treatment and has reported aphrodisiac properties. The pharmacological actions of the roots of C. alba have been described in the Pharmacopoeias of several European nations since the last century; in Brazil, it is commercialized in free markets as an adulterant of the Brazilian 'Ipecac'.
Preparation Methods in Traditional Contexts
Root infusion is used in traditional medicine as antirheumatic, antiasthmatic, diuretic, anti-inflammatory, and antimicrobial.
The dominant mode of traditional preparation is a decoction or aqueous infusion of the roots, consumed orally. The roots were also used topically in some traditions for snakebites and skin conditions.
Key Constituents and Active Compounds
Overview of Phytochemical Diversity
A large number of plant specialized metabolites have been isolated from C. alba, including lignans, coumarins, ketoalcohols, triterpenes, iridoids, quinoline alkaloids, flavonoids, and saponins. Chiococca alba is also a rich source of diterpenes, including merilactone and ribenone.
From a scientific perspective, Chiococca alba has attracted interest due to its rich phytochemical profile, including compounds such as flavonoids, saponins, and alkaloids.
Iridoids and Seco-Iridoid Glucosides
Phytochemical investigation of Chiococca alba afforded three new iridoids — alboside I, alboside II, and alboside III — and a new seco-iridoid, alboside V. Alboside IV showed moderate activity towards the DNA repair-deficient mutant RS321 of Saccharomyces cerevisiae.
These compounds, identified initially by Carbonezi et al. (1999) using NMR spectroscopy and mass spectrometry, represent a structurally novel class of iridoid glucosides specific to this species.
Triterpene Saponins (Chiococcasaponins)
Five triterpenoidal saponins were isolated from the roots of Chiococca alba (L.) Hitchc. (Rubiaceae).
The saponins of Chiococca alba are triterpene bidesmosides that contain glycidic moieties attached to the C-3 and C-28 carbon of their aglycone. Their adjuvant potential increases in direct relationship to the length and hydrophilicity of the C-28 attached sugar chain, which contains: arabinose-rhamnose in CA2; arabinose-rhamnose-xylose in CA3X; arabinose-rhamnose-apiose in CA3; and arabinose-rhamnose-apiose-apiose in CA4 saponin.
Diterpenes: Merilactone and Ribenone
Chiococca alba is also a rich source of diterpenes, including merilactone and ribenone. Merilactone is a structurally unique C19 nor-diterpene found only in C. alba. It is potentially synthesized from a diterpene scaffold, followed by ring cleavage, carbon loss, and lactonization. Ribenone has an unusual heteroatom-containing ring with demonstrated activity against Leishmania and potential anti-cancer activity.
Two new ent-kaurane diterpenes — 1-hydroxy-18-nor-kaur-4,16-dien-3-one (1) and 15-hydroxy-kaur-16-en-3-one (2) — along with four known metabolites (kaur-16-en-19-ol, kaurenoic acid, merilactone, and ribenone) and a mixture of stigmasterol and β-sitosterol were isolated from the ethanolic root extract of Chiococca alba.
Quinoline Alkaloids
Two biologically active quinoline alkaloids, an oleanane-type triterpene, an ent-kaurane, an iridoid and a seco-iridoid, and a nor-seco-pimarane known as merilactone have been isolated from Chiococca alba roots, while lignans, coumarins, and two new keto alcohols have been found in the leaves.
Flavonoids
The five major compounds identified in methanolic extracts of C. alba were rutin, naringin, myricetin, morin, and quercetin.
Phytochemical analysis also revealed the presence of flavonoids, coumarins, and phenolic acids in C. alba extracts.
Ketoalcohols, Lignans, and Coumarins from Leaves
Two new hydroxyketones — 4-hydroxyheptadecan-7-one and 5-hydroxyoctadecan-11-one — along with 5,7,4'-trimethoxy-4-phenylcoumarin, exostemin, matairesinol, and d-mannitol have been isolated from the leaves of Chiococca alba and identified by spectral data and chemical studies.
Fatty Acids and Ursolic Acid
A preliminary analysis of the ethanolic extract of C. alba by GC-MS revealed the presence of linear chain fatty acids (hexadecanoic, octadecanoic, eicosanoic, docosanoic, and tetracosanoic acids), with hexadecanoic acid the predominant fatty acid, as well as a triterpenoid constituent identified as ursolic acid.
Genome and Biosynthetic Pathways
A 558 Mb draft genome assembly for C. alba was generated, encoding 28,707 high-confidence genes. Comparative analyses with other angiosperm genomes revealed enrichment in snowberry of lineage-specific genes involved in specialized metabolism.
A total of 27 putative terpene synthase genes were identified, including 10 encoding diterpene synthases. Functional validation of a subset of putative terpene synthases revealed that combinations of diterpene synthases yielded access to products of both general and specialized metabolism. Plausible intermediates in the biosynthesis of merilactone and ribenone — structurally unique antimicrobial diterpene natural products — were specifically identified.
Scientific Evidence by Area of Activity
Anti-Inflammatory Activity
Studies on the pharmacological properties of Chiococca alba and its constituents have revealed anti-inflammatory effects (Schapoval et al., 1983), antimicrobial action against Staphylococcus aureus (Borges-Argáez et al., 1997), and anticancer activity (Carbonezi et al., 1997).
Two new oleanane saponins — chiococcasaponin III and chiococcasaponin IV — were isolated and structurally characterized. The saponin fractions of C. alba roots were evaluated for activity against in vitro lipopolysaccharide-induced inflammation. The results strongly support fractions I, III, and IV as having anti-inflammatory properties.
Evidence strength: Preclinical only. All anti-inflammatory evidence to date comes from in vitro cell-based assays and earlier animal pharmacological studies. No controlled human clinical trials on the anti-inflammatory properties of C. alba have been published.
Antimicrobial Activity
Contemporary research has validated the use of C. alba as a folk medicine by confirming its anti-inflammatory and anti-microbial properties.
Bioassay-guided purification of the methanolic crude root extract resulted in isolation of the metabolite ent-17-hydroxy-16α-kauran-3-one, which showed weak antimicrobial activity when tested against Staphylococcus aureus.
The components of C. alba extracts may vary as a result of different ecological conditions, such as the type of soil, climate, degree of maturity, and physiological development of the plant.
Evidence strength: Preclinical (in vitro). Antimicrobial activity against Staphylococcus aureus has been demonstrated at the laboratory level with specific fractions; clinical evidence in humans is absent.
Antiviral Activity
Chiococca alba, a Neotropical plant traditionally used by Yucatec Maya healers as an antipyretic and antirheumatic, may hold potential as a source of antiviral agents. This study aimed to evaluate the antiviral potential of C. alba methanolic extracts (CAH21 and CAH24) against Chikungunya virus (CHIKV) and Mayaro virus (MAYV) through preliminary in vitro and in silico analyses. The cytotoxicity of two methanolic extracts from C. alba roots was assessed in Vero cells using the neutral red assay, and viral activity was determined via plaque assay post-treatment.
In vitro assays demonstrated that both extracts inhibited over 70% of activity against CHIKV and MAYV at a concentration of 60 µg/mL. In silico predictions suggested that the flavonoids naringin and vitexin had the highest affinity for the nsP2 proteases of CHIKV and MAYV, indicating their potential as viral inhibitors.
Evidence strength: Preliminary in vitro and in silico only. These findings are exploratory; no human clinical trials on antiviral use have been conducted.
Larvicidal and Insect Repellent Activity
Chromatographic analysis of methanolic extracts of C. alba revealed 18 compounds, including rutin, naringin, myricetin, morin, and quercetin. The methanolic extracts of C. alba showed larvicidal activity (LC50 = 82 [72–94] mg/mL) without killing or affecting the predatory ability of non-target organisms (B. anurum prey upon mosquito larvae).
In silico predictions revealed the molecular interactions between rutin and the AeagOBP1 receptor to be one possible mechanism for the repellent potential recorded for formulations containing C. alba extracts. Low cytotoxicity against mammalian cell lines reinforces the selectivity of C. alba extracts. These findings highlight the potential of C. alba and one of its constituents (rutin) as alternative tools in the management of Aedes aegypti mosquitoes.
Evidence strength: Preclinical in vitro/in silico. No human repellent or vector control clinical studies have been reported.
Anticancer Potential
Tests with the DNA-repair deficient Saccharomyces cerevisiae mutant RS321 suggest that C. alba may have anti-cancer activity.
Ribenone has an unusual heteroatom-containing ring with demonstrated activity against Leishmania and potential anti-cancer activity.
Evidence strength: Highly preliminary. Anticancer observations are restricted to yeast-model bioassays and isolated compound studies. No animal tumor models or human data exist in the published record for this plant.
Immunological Adjuvant Activity (Saponins)
The saponins of Chiococca alba are triterpene bidesmosides containing glycidic moieties attached to C-3 and C-28 of their aglycone. Their adjuvant potential increases in direct relationship to the length and hydrophilicity of the C-28 attached sugar chain. The hydrophile/lipophile balance calculated for CA2 was 12.7, for CA3 and CA3X was 15.8, and for CA4 was 19.9.
The increase in sugar units of the saponins is positively correlated to the increase of intradermal response (IDR) and to the decrease of parasite load in Leishmania models.
C. alba saponins were non-toxic and only the xylose-containing saponin CA3X was hemolytic (HD50 = 87 µg/mL).
These saponins have been studied as adjuvants in the context of the Leishmune® canine vaccine against visceral leishmaniasis. This represents an area of applied use at the preclinical/veterinary level rather than in direct human supplementation.
Diuretic and Renal Effects
Chiococca alba is reported to be used in folk medicine as a tonic for ganglion inflammation and as a diuretic.
Its traditional use as a diuretic has been repeatedly described across multiple cultural traditions, but no clinical studies quantifying diuretic output in humans have been published.
Body Systems and Health Areas Associated with David's Milkberry
- Musculoskeletal / Rheumatic: Root infusion used as antirheumatic; historical European pharmacopoeial recognition for this indication.
- Immune and Infectious Disease: Contemporary research has confirmed anti-microbial properties; in vitro antiviral activity demonstrated against arboviruses.
- Renal / Urinary: In some cultures, the plant has played a role in addressing kidney and urinary tract issues.
- Respiratory: It has been employed as a natural remedy for respiratory conditions such as coughs, bronchitis, and asthma, owing to its expectorant qualities.
- Gastrointestinal: The roots are used as laxatives, emetic diuretics, and antidiarrheals.
- Antiparasitic (Veterinary): Saponins evaluated as vaccine adjuvants against visceral leishmaniasis in animal models.
- Vector control: Methanolic extracts highlight the potential of C. alba and rutin as alternative tools in the management of Aedes aegypti mosquitoes.
Dosage Forms and Dosages Reported in Studies
There are no established human clinical dosages for Chiococca alba in the peer-reviewed literature. Dosages referenced in the scientific record are exclusively from preclinical (animal) toxicological or pharmacological studies.
- Acute oral toxicity in mice (ethanolic root extract):
The toxicological study evaluated an ethanolic extract (EE) of Chiococca alba roots. Single oral doses of EE caused hypoactivity, but no deaths were noted up to the highest dose tested (2000 mg/kg). EE at 500 mg/kg by oral route reduced mouse locomotion in the open field test.
- Subacute oral toxicity (repeated gavage, 14 days):
Repeated administration of EE by gavage for 14 days caused no deaths.
- Subacute intraperitoneal toxicity:
Administration of EE by the intraperitoneal (i.p.) route for 14 days decreased weight gain and caused anemia, neutrophilia, and deaths. The no-observed-adverse-effect level (NOAEL) for subacute treatment by the i.p. route was as low as 15.6 mg of EE/kg body weight/day.
- Antiviral assay concentration (in vitro):
In vitro assays demonstrated that both extracts inhibited over 70% of activity against CHIKV and MAYV at a concentration of 60 µg/mL.
No standardized dosage has been validated in human subjects. Traditional preparations (root decoctions) are administered in quantities not formally quantified in the published scientific literature.
Safety Considerations
Oral Route Toxicity
The ethanolic extract (EE) of C. alba roots was not mutagenic in the Salmonella/microsome assay with TA100, TA98, TA97a, and TA1535 strains. In summary, EE was not mutagenic and presented a low acute and subacute toxicity by the oral route. Toxicities by parenteral routes, however, were more pronounced.
Parenteral Route Toxicity
EE was markedly more toxic when given by intraperitoneal (i.p.) and subcutaneous (s.c.) routes. Acute approximate lethal doses (ALD) were 125 mg/kg (males) and 250 mg/kg (females) by i.p. route, and 250 mg/kg (both sexes) by s.c. route.
Deaths after single doses by these routes were preceded by hypoactivity, ataxia, and lethargy.
Liver Enzyme Activity
Activity of liver monooxygenases (pentoxy- and ethoxyresorufin-O-dealkylases) was not altered by repeated treatment with EE (2000 mg/kg/day by the oral route).
This finding suggests a low propensity for cytochrome P450 enzyme modulation at the oral doses tested in mice, though formal drug interaction studies in humans have not been published.
Saponin-Specific Safety
C. alba saponins were non-toxic, and only the xylose-containing saponin CA3X was hemolytic (HD50 = 87 µg/mL).
This hemolytic potential is relevant principally to parenteral administration contexts (e.g., vaccine adjuvant formulations) and is not a documented concern at normal oral use levels, though no formal oral hemolysis studies have been published.
Absence of Clinical Safety Data
Notwithstanding the widespread medicinal use of Chiococca alba root extracts in Brazil and elsewhere, there is no published study on their full toxicological properties in humans. It should be borne in mind that tradition in use by no means warrants that a medicinal plant is safe, particularly with regard to mutagenicity and carcinogenicity, because cause–effect relationships in these areas are rather complex.
Variable Phytochemistry
The components of C. alba extracts may vary as a result of different ecological conditions, such as the type of soil, climate, degree of maturity, and physiological development of the plant.
This variability means that the safety and activity profile of commercial preparations could differ substantially from those of the extracts studied in published research.
Ipecac Adulteration
In Brazil, C. alba is commercialized in free markets as an adulterant of the Brazilian 'Ipecac'.
This practice introduces a risk of product misidentification, as true ipecac (Carapichea ipecacuanha) contains potent emetic alkaloids (emetine and cephaeline) at pharmacologically significant concentrations. Consumers obtaining unlabeled root material should be aware of this documented adulteration risk.
References
Go back